“Cytokinetics Announces Opening of Phase IIb Clinical Trial of Intravenous Formulation of Omecamtiv Mecarbil in Patients With Acute Heart Failure”

“SOUTH SAN FRANCISCO, CA–(Marketwire – April 19, 2011) – Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the opening to enrollment of a Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil. This trial is being conducted by Amgen in collaboration with Cytokinetics and is designed to evaluate the safety and efficacy of omecamtiv mecarbil in patients with left ventricular systolic dysfunction who are hospitalized for acute heart failure. Amgen holds an exclusive, worldwide (excluding Japan) license to omecamtiv mecarbil and related compounds, subject to specified development and commercialization participation rights of Cytokinetics.”

This entry was posted in Uncategorized. Bookmark the permalink.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s